Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ethylnorepinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 0.55 |
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.55 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.55 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.55 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.53 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.53 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.50 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.50 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.50 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.50 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.50 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.50 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.50 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 6/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylnorepinephrine SCHEMBL75742 | 1.00 | KDM4E (1.00) | KDM4ETDP1MAPK1RECQLMAPT | |
| Ethylnorepinephrine SCHEMBL29711047 | 0.98 | TDP1 (0.96) | KDM4ETDP1MAPK1RECQLMAPT | |
| Ethylnorepinephrine SCHEMBL249736 | 0.98 | TDP1 (0.96) | KDM4ETDP1MAPK1RECQLMAPT | |
| Hydrochloric Acid SCHEMBL10924534 | 0.84 | TDP1 (0.72) | KDM4ETDP1MAPK1RECQLMAPT | |
| SCHEMBL10802005 | 0.81 | TDP1 (0.69) | KDM4ETDP1MAPK1RECQLMAPT | |
| Ethylnorepinephrine SCHEMBL3130770 | 0.80 | KDM4E (0.64) | KDM4ETDP1MAPK1RECQLMAPT | |
| Levonordefrin SCHEMBL363800 | 0.79 | KDM4E (1.00) | KDM4ETDP1MAPK1RECQLMAPT | |
| Nordefrin SCHEMBL5060952 | 0.79 | KDM4E (1.00) | KDM4ETDP1MAPK1RECQLMAPT | |
| Nordefrin SCHEMBL316522 | 0.79 | KDM4E (1.00) | KDM4ETDP1MAPK1RECQLMAPT | |
| SCHEMBL18159498 | 0.78 | KDM4E (0.64) | KDM4ETDP1MAPK1RECQLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029085-A1 | STABILIZATION OF QUINOL COMPOSITION SUCH AS CATECHOLAMINE DRUGS | MACKAY JON (US) | 2012-02-02 | — | — | US | claimed |
| CN-101506159-A | Compounds having CRTH2 antagonist activity | OXAGEN LTD (GB) | 2009-08-12 | — | — | CN | claimed |
| CN-110177780-A | Pyrimidine compound containing acidic groups | 阿普罗斯治疗公司 | 2019-08-27 | — | — | CN | disclosed |
| CN-101489575-B | FKBP-L and use thereof | ALMAC DISCOVERY LTD | 2013-08-28 | — | — | CN | disclosed |
| CN-103012376-A | Amide derivatives | ASTRAZENECA AB | 2013-04-03 | — | — | CN | disclosed |
| CN-101506159-B | Compounds having CRTH2 antagonist activity | OXAGEN LTD | 2012-08-22 | — | — | CN | disclosed |
| US-20120029085-A1 | STABILIZATION OF QUINOL COMPOSITION SUCH AS CATECHOLAMINE DRUGS | MACKAY JON (US) | 2012-02-02 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| CN-1918134-B | Amide derivatives with cyclopropylaminocarbonyl substituents as cytokine inhibitors | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | CN | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| CN-101687932-A | Binding members for ige molecules | ASTRAZENECA AB | 2010-03-31 | — | — | CN | disclosed |
| CN-101675079-A | Binding members for ige molecules | ASTRAZENECA AB | 2010-03-17 | — | — | CN | disclosed |
| CN-101506159-A | Compounds having CRTH2 antagonist activity | OXAGEN LTD (GB) | 2009-08-12 | — | — | CN | disclosed |
| CN-101489575-A | FKBP-L and use thereof | ALMAC DISCOVERY LTD (GB) | 2009-07-22 | — | — | CN | disclosed |
| CN-1918134-A | Amide derivatives with cyclopropylaminocarbonyl substituents as cytokine inhibitors | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| CN-1898216-A | Amide derivatives | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | CN | disclosed |
| CN-1732006-A | 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide derivatives as P2X7-inhibitors for the treatment of inflammatory diseases | PFIZER PROD INC (US) | 2006-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029085-A1 | STABILIZATION OF QUINOL COMPOSITION SUCH AS CATECHOLAMINE DRUGS | ADRA2C, ADRB2, ADRB1 | ADRB2 2/4885PTGS2 502/4885OPRK1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.